Small Cap Gainers: TRIL, CIO, ENDP
3:56 pm Monday, August 23rd, 2021
Trillium Therapeutics Inc (NASDAQ: TRIL) Pfizer (PFE) agreed to acquire all of the outstanding shares of co that it does not already own for an implied equity value of $2.26 billion, or $18.50/share in cash, to strengthen its position in immuno-oncology. The stock rises to its highest levels since December.
City Office REIT Inc (NYSE: CIO) announced that it entered into agreements to sell all of its holdings San Diego’s Sorrento Mesa submarket for $576 million; the properties are to be sold unencumbered by debt, and the transactions are expected to generate net proceeds of approx. $546 million. At record highs. City Office REIT, Inc. (NYSE: CIO) invests in high-quality office properties in 18-hour cities with strong economic fundamentals, primarily in the Southern and Western United States. At September 30, 2020, CIO owned office complexes comprising 5.8 million square feet of net rentable area.
Endo International PLC (NASDAQ: ENDP) continued volatility; posts a rebound after falling late last week on reports that co has hired a financial restructuring adviser in the face of opioid-related lawsuits. Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren’s contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain.
